GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

YCBD · Mar 31, 2025

cbdMD, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-25-017178General Corporate
Capex intensity25thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.33% · OPTIONAL · VALID

Revenue growth100thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

8.52% · CORE · VALID

Inventory pressure50thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

60.73% · OPTIONAL · VALID

Gross margin33thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_margin

62.31% · CORE · VALID

Operating margin83thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-10.23% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History18 statesSelf-history eligible
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
3.21%
Current
0.33%
Delta
-2.89%
Growth Increased
Previous
-4.87%
Current
8.52%
Delta
13.39%
Inventory Pressure Increased
Previous
48.36%
Current
60.73%
Delta
12.37%
Margin Decreased
Previous
66.50%
Current
62.31%
Delta
-4.19%
Profitability Decreased
Previous
-1.69%
Current
-10.23%
Delta
-8.54%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.